

## AMENDMENTS TO THE CLAIMS

After entry into the U.S. national stage, and assurance of a U.S. filing date, the present document amends the claims from the PCT application by amending claims 1-27 and 30-57 and adding claims 58-76. According to 37 C.F.R. § 1.121(c), after entry of the present amendment, the status of the claims in the case is as follows:

1. (Currently Amended) A method for decreasing ~~calorie intake in a subject, a method for decreasing appetite in a subject, a method for decreasing food intake in a subject, a method for weight control or treatment in a subject, or a method for reduction or prevention of appetite,~~ reducing hunger or sensations of hunger, increasing satiety or sensations of satiety, decreasing food intake, decreasing calorie intake, reducing nutrient availability, increasing energy expenditure, preventing, reducing or treating weight gain, inducing or promoting weight loss, maintaining a desired body weight or a desired Body Mass Index, or reducing or preventing obesity in a subject, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject.
2. (Currently Amended) A method for ~~preventing and reducing weight gain in a subject; a method for inducing and promoting weight loss in a subject; or a method for reducing obesity in a subject as measured by the Body Mass Index, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject~~ as claimed in claim 1, wherein said method

prevents weight gain, induces weight loss, maintains a desired body weight or a desired Body Mass Index or reduces obesity in said subject as measured by the Body Mass Index.

3. (Currently Amended) A method ~~for controlling of any one or more of appetite, satiety and hunger in a subject, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject~~ as claimed in claim 1, wherein said method decreases appetite, reduces hunger or sensations of hunger, or increases satiety or sensations of satiety in said subject.

4. (Currently Amended) A method as claimed in ~~claim 3 for inducing, increasing, enhancing or promoting satiety and/or sensations of satiety in a subject, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject~~ claim 1, wherein a therapeutically effective amount of PYY is administered to said subject.

5. (Currently Amended) A method as claimed in ~~claim 3 for reducing, inhibiting or suppressing hunger or sensations of hunger in a subject, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject~~ claim 1, wherein a therapeutically effective amount of GLP-1 is administered to said subject.

6. (Currently Amended) A method ~~for maintaining desired body weight, a desired Body Mass Index, and/or a desired appearance and good health in a subject, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject~~ as claimed in claim 1, wherein a therapeutically effective amount of PYY and a therapeutically effective amount of GLP-1 is administered to said subject.

7. (Currently Amended) A method ~~for improving lipid profile in a subject, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject~~ as claimed in claim 1, wherein said method improves the lipid profile in said subject.

8. (Currently Amended) A method ~~for alleviating a condition or disorder which can be alleviated by reducing nutrient availability, which comprises peripherally administering a therapeutically effective amount of PYY or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof to the subject~~ as claimed in claim 1, wherein said method alleviates a condition or disorder in said subject that can be alleviated by reducing nutrient availability.

9. (Currently Amended) A method as claimed in ~~any one of claims 1 to 8~~ claim 1, wherein the PYY or agonist thereof and the GLP-1 or agonist thereof are administered ~~simultaneously or to said subject~~ sequentially.

10. (Currently Amended) A method as claimed in ~~any one of claims 1 to 9~~ claim 9, wherein the PYY or agonist thereof and the GLP-1 or agonist thereof are administered to said subject via different routes.
11. (Currently Amended) A method as claimed in ~~any one of claims 1 to 10~~ claim 1, wherein the subject is overweight.
12. (Currently Amended) A method as claimed in ~~any one of claims 1 to 11~~ claim 1, wherein the subject is obese.
13. (Currently Amended) A method as claimed in ~~any one of claims 1 to 12~~ claim 1, wherein the subject is diabetic.
14. (Currently Amended) A method as claimed in ~~any one of claims 1 to 13~~ claim 1, wherein peripheral administration comprises subcutaneous, intravenous, intramuscular, intranasal, transdermal, intracisternal, intravaginal, intraperitoneal, oral, topical, transmucosal, rectal or sublingual administration or pulmonary inhalation.
15. (Currently Amended) A method as claimed in ~~any one of claims 1 to 14~~ claim 70, wherein peripherally administering PYY or the agonist thereof comprises administering about 45 to about 135 pmol of PYY or the agonist thereof per kilogram body weight of the subject.

16. (Currently Amended) A method as claimed in claim 15, wherein peripherally administering PYY or the agonist thereof comprises administering about 72 pmol of PYY or the agonist thereof per kilogram body weight of the subject.

17. (Currently Amended) A method as claimed in ~~claim 15~~ claim 1, wherein ~~peripherally administering the PYY or the agonist thereof comprises administering about 45 to about 135 pmol per kilogram body weight of~~ or the GLP-1 or agonist thereof is peripherally administered to the subject at least 30 minutes prior to a meal.

18. (Currently Amended) A method as claimed in ~~any one of claims 1 to 14,~~ wherein ~~peripherally administering the therapeutically effective amount of PYY or the agonist thereof comprises administering PYY or an agonist thereof to the subject in a multitude of doses, wherein each dose in the multitude of doses comprises administration of about 0.5 to about 135 pmol per kilogram of body weight at least about 30 minutes prior to a meal~~ claim 1, wherein the PYY or the agonist thereof or the GLP-1 or agonist thereof is peripherally administered to the subject in multiple or divided doses.

19. (Currently Amended) A method as claimed in ~~any one of claims 1 to 18~~ claim 1, wherein the PYY or the agonist thereof and the GLP-1 or agonist thereof is administered in an amount sufficient to decrease calorie intake in said subject for a period of at least about 2 hours.

20. (Currently Amended) A method as claimed in ~~any~~ claim 19, wherein the PYY or the agonist thereof and the GLP-1 or agonist thereof is administered in an amount sufficient to decrease calorie intake in said subject for a period of about 2 to ~~12~~ 24 hours.

21. (Currently Amended) A method as claimed in ~~any one of claims 1 to 14~~ claim 1, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 0.1 nmoles per kg body weight ~~of the subject or more, for example, 0.2 nmoles or more, for example, 0.4 nmoles or more, for example, 0.6 nmoles or more, for example, 0.8 nmoles or more, for example, 1.0 nmoles or more, for example, 1.2 nmoles or more, for example, 1.4 nmoles or more, for example, 1.6 nmoles or more, for example, 1.8 nmoles or more, for example, 2.0 nmoles or more, for example, 2.2 nmoles or more, for example, 2.4 nmoles or more, for example, 2.6 nmoles or more, for example, 2.8 nmoles, for example, 3.0 nmoles or more, for example,~~ up to 3.2 nmoles per kg body weight of the subject.

22. (Currently Amended) A method as claimed in ~~any one of claims 1 to 14 or claim 21~~, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally ~~in an amount~~ at a dose of ~~up to 3.0 nmoles per kg body weight, for example, up to 2.8 nmoles, for example, up to 2.6 nmoles, for example, up to 2.4 nmoles, for example, up to 2.2 nmoles, for example, up to 2.0 nmoles, for example, up to 1.8 nmoles, for example, up to 1.4 nmoles, for example, up to 1.2 nmoles, for example, up to 1.0 nmoles, for example, up to 0.8 nmoles, for example, up to 0.6 nmoles, for example, up to 0.4 nmoles, for example, up to 0.2 nmoles per kg body weight~~ up to 3.0 nmoles per kg body weight of the subject.

23. (Currently Amended) A method as claimed in ~~any one of claims 1 to 14, 21 and 22~~ claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 0.1 nmoles per kg body weight of the subject ~~or more, for example, 0.2 nmoles or more, for example, 0.4 nmoles or more, for example, 0.6 nmoles or more, for example, 0.8 nmoles or more, for example, 1.0 nmole or more, for example, 1.2 nmoles or more, for example, 1.4 nmoles or more, for example, 1.6 nmoles or more, for example, 1.8 nmoles or more, for example, 2.0 nmoles or more, for example, 2.2 nmoles or more, for example, 2.4 nmoles or more, for example, 2.6 nmoles or more, for example, 2.8 nmoles, for example, 3.0 nmoles or more, for example, up to 3.2 nmoles per kg body weight.~~

24. (Currently Amended) A method as claimed in ~~any one of claims 1 to 14 and 21 to 23~~ claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally ~~in an amount at a dose of up to 3.0 nmoles per kg body weight, for example, up to 2.8 nmoles, for example, up to 2.6 nmoles, for example, up to 2.4 nmoles, for example, up to 2.2 nmoles, for example, up to 2.0 nmoles, for example, up to 1.8 nmoles, for example, up to 1.4 nmoles, for example, up to 1.2 nmoles, for example, up to 1.0 nmoles, for example, up to 0.8 nmoles, for example, up to 0.6 nmoles, for example, up to 0.4 nmoles, for example, up to 0.2 nmoles per kg body weight~~ of the subject.

25. (Currently Amended) A method as claimed in ~~any one of claims 1 to 24~~ claim 35, wherein the PYY agonist comprises a molecule that specifically binds the Y2 receptor.

26. (Currently Amended) A method as claimed in claim 25, wherein the PYY agonist increases the expression of c-fos in a section of an arcuate nucleus contacted with the ~~compound~~ PYY agonist.

27. (Currently Amended) A method as claimed in ~~any one of claims 1 to 24~~ claim 35, wherein the PYY agonist specifically binds to a neuropeptide Y neuron and inhibits an activity of a neuropeptide Y neuron.

28. (Original) A method as claimed in claim 27, wherein the PYY agonist decreases the action potential firing rate of the neuropeptide Y neuron.

29. (Original) A method as claimed in claim 27, wherein the neuropeptide Y neuron synapses with a proopiomelanocortin neuron, and wherein binding of the PYY agonist to the neuropeptide Y neuron results in an increased activity of the proopiomelanocortin neuron.

30. (Currently Amended) A method as claimed in claim ~~27~~ 29, wherein the decreased activity of the neuropeptide Y neuron results in an increase in action potential firing on the proopiomelanocortin neuron.

31. (Currently Amended) A method as claimed in ~~any one of claims 1 to 30~~ claim 36, wherein the GLP-1 agonist is exendin-4 or a derivative thereof that is a GLP-1 agonist.



32. (Currently Amended) A method as claimed in ~~any one of claims 1 to 31~~ claim 73, further comprising administering a therapeutically effective amount of amfepramone (diethylpropion), phentermine, mazindol, phenylpropanolamine, fenfluramine, dexfenfluramine, or fluoxetine to said subject.

33. (Currently Amended) A method as claimed in ~~any one of claims 1 to 32~~ claim 1, wherein the subject is human.

34. (Currently Amended) ~~Use of PYY and an agonist thereof and GLP-1 or an agonist thereof for the manufacture of a medicament or medicaments for use in a method as defined in any one of claims 1 to 33~~ A method as claimed in claim 1, wherein the PYY or agonist thereof and the GLP-1 or agonist thereof are administered to said subject substantially simultaneously.

35. (Currently Amended) ~~Use of PYY and an agonist thereof in the manufacture of a medicament for use, in combination with GLP-1 or an agonist thereof, in a method for decreasing caloric intake in a subject, a method for decreasing appetite in a subject, a method for decreasing food intake in a subject, a method for weight control or treatment in a subject, or a method for reduction or prevention of obesity in a subject~~ A method as claimed in claim 1, wherein a therapeutically effective amount of a PYY agonist is administered to said subject.

36. (Currently Amended) ~~Use of PYY and an agonist thereof in the manufacture of a medicament for use, in combination with GLP-1 or an agonist thereof, in a method for preventing and reducing weight gain in a subject; a method for inducing and promoting weight loss in a~~

~~subject; or a method for reducing obesity in a subject as measured by the Body Mass Index~~ A method as claimed in claim 1, wherein a therapeutically effective amount of a GLP-1 agonist is administered to said subject.

37. (Currently Amended) ~~Use of PYY and an agonist thereof in the manufacture of a medicament for use, in combination with GLP 1 or an agonist thereof, in a method for controlling of any one or more of appetite, satiety and hunger in a subject~~ A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 0.4 nmoles per kg body weight of the subject

38. (Currently Amended) ~~Use of PYY and an agonist thereof in the manufacture of a medicament for use, in combination with GLP 1 or an agonist thereof, in a method for inducing, increasing, enhancing or promoting satiety and/or sensations of satiety in a subject~~ A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 0.6 nmoles per kg body weight of the subject

39. (Currently Amended) ~~Use of PYY and an agonist thereof in the manufacture of a medicament for use, in combination with GLP 1 or an agonist thereof, in a method for reducing, inhibiting or suppressing hunger or sensations of hunger in a subject~~ A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 0.8 nmoles per kg body weight of the subject

40. ~~(Currently Amended) Use of PYY and an agonist thereof in the manufacture of a medicament for use, in combination with GLP-1 or an agonist thereof, in a method for maintaining desired body weight, a desired Body Mass Index, and/or a desired appearance and good health in a subject~~ A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 1.0 nmoles per kg body weight of the subject.

41. ~~(Currently Amended) Use of PYY and an agonist thereof in the manufacture of a medicament for use, in combination with GLP-1 or an agonist thereof, in a method for improving lipid profile in a subject~~ A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 1.2 nmoles per kg body weight of the subject.

42. ~~(Currently Amended) Use of PYY and an agonist thereof in the manufacture of a medicament for use, in combination with GLP-1 or an agonist thereof, in a method for alleviating a condition or disorder which can be alleviated by reducing nutrient availability~~ A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 1.4 nmoles per kg body weight of the subject.

43. ~~(Currently Amended) Use as claimed in any one of claims 31 to 41, wherein the PYY or agonist thereof and the GLP-1 or agonist thereof are administered simultaneously, or sequentially in either order~~ A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the

GLP-1 or agonist thereof is administered peripherally at a dose of 1.6 nmoles per kg body weight of the subject.

44. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of PYY ~~and~~ or an agonist thereof and a therapeutically effective amount of GLP-1 or an agonist thereof, in admixture or conjunction with a pharmaceutically suitable carrier.

45. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of PYY or an agonist thereof in admixture with a pharmaceutically suitable carrier, ~~in a form suitable~~ for subcutaneous administration.

46. (Currently Amended) A pharmaceutical composition as claimed in claim 45, which comprises 10 nmoles ~~or more, for example,~~ 20 nmoles ~~or more, for example,~~ 30 nmoles ~~or more, for example,~~ 40 nmoles ~~or more~~ of PYY or an agonist thereof.

47. (Currently Amended) A pharmaceutical composition as claimed in claim ~~46~~ 45, which comprises from 20 to 60 nmoles, ~~for example,~~ or 35 to 45 nmoles of PYY or an agonist thereof.

48. (Currently Amended) A pharmaceutical composition as claimed in claim 45, which comprises ~~from~~ PYY or an agonist thereof in an amount suitable for subcutaneous administration ~~peripherally in an amount of 0.1 nmoles up to 3.0~~ 3.2 nmoles per kg body weight, ~~for example,~~ up to 2.8 nmoles, ~~for example,~~ up to 2.6 nmoles, ~~for example,~~ up to 2.4 nmoles, ~~for example,~~ up

~~to 2.2 nmoles, for example, up to 2.0 nmoles, for example, up to 1.8 nmoles, for example, up to 1.4 nmoles, for example, up to 1.2 nmoles, for example, up to 1.0 nmoles, for example, up to 0.8 nmoles, for example, up to 0.6 nmoles, for example, up to 0.4 nmoles, for example, up to 0.2 nmoles per kg body weight.~~

49. (Currently Amended) A pharmaceutical composition as claimed in claim 45, which comprises ~~from~~ PYY or an agonist thereof in an amount suitable for subcutaneous administration ~~peripherally in an amount of 0.1 nmoles per kg body weight of the subject or more, for example, 0.2 nmoles or more, for example, 0.4 nmoles or more, for example, 0.6 nmoles or more, for example, 0.8 nmoles or more, for example, 1.0 nmole or more, for example, 1.2 nmoles or more, for example, 1.4 nmoles or more, for example, 1.6 nmoles or more, for example, 1.8 nmoles or more, for example, 2.0 nmoles or more, for example, 2.2 nmoles or more, for example, 2.4 nmoles or more, for example, 2.6 nmoles or more, for example, 2.8 nmoles, for example, 3.0 nmoles or more, for example, up to 3.2~~ 3.0 nmoles per kg body weight.

50. (Currently Amended) A pharmaceutical composition as claimed in claim ~~48 or 49~~ 45, in unit dosage form.

51. (Currently Amended) A method as ~~defined in any one of claims 1 to 8~~ claimed in claim 1, which comprises administering PYY or an agonist thereof to the subject subcutaneously at a dose of 10 nmoles ~~or more, for example, 20 nmoles or more, for example, 30 nmoles or more, for example, 40 nmoles or more~~ to the subject of the method.

52. (Currently Amended) ~~A method as claimed in claim 51, wherein from 20 to 60 nmoles, for example, 35 to 45 nmoles of PYY or an agonist thereof are administered~~ claim 1, which comprises administering PYY or an agonist thereof to the subject subcutaneously at a dose of 20 to 60 nmoles, or 35 to 45 nmoles.

53. (Currently Amended) ~~Use of PYY or an agonist thereof for the manufacture of a composition for subcutaneous administration to a subject for treatment of the subject by a method as defined in any one of claims 1 to 8~~ A method for decreasing appetite, reducing hunger or sensations of hunger, increasing satiety or sensations of satiety, decreasing food intake, decreasing calorie intake, reducing nutrient availability, increasing energy expenditure, preventing, reducing or treating weight gain, inducing or promoting weight loss, maintaining a desired body weight or a desired Body Mass Index, or reducing or preventing obesity in a subject, which comprises administering to said subject a therapeutically effective amount of PYY or an agonist thereof by subcutaneous administration.

54. (Currently Amended) ~~Use as claimed in claim 53, wherein the treatment comprises administering PYY or an agonist thereof subcutaneously at a dose of 10 nmoles or more, for example, 20 nmoles or more, for example, 30 nmoles or more, for example, 40 nmoles or more to the subject~~ A method as claimed in claim 53, which comprises administering PYY or an agonist thereof to the subject subcutaneously at a dose of 10 nmoles, 20 nmoles, 30 nmoles or 40 nmoles.

55. (Currently Amended) ~~Use as claimed in claim 54, wherein the treatment comprises administering PYY or an agonist thereof subcutaneously at a dose of from 20 to 60 nmoles, for example, 35 to 45 nmoles to the subject~~ A method as claimed in claim 53, which comprises administering PYY or an agonist thereof to the subject subcutaneously at a dose of 20 to 60 nmoles, or 35 to 45 nmoles.

56. (Currently Amended) ~~Use as claimed in claim 53, wherein the PYY or agonist thereof is administered peripherally at a dose of 0.1 nmoles or more per kg body weight of the subject, for example, 0.2 nmoles or more, for example, 0.4 nmoles or more, for example, 0.6 nmoles or more, for example, 0.8 nmoles or more, for example, 1.0 nmole or more, for example, 1.2 nmoles or more, for example, 1.4 nmoles or more, for example, 1.6 nmoles or more, for example, 1.8 nmoles or more, for example, 2.0 nmoles or more, for example, 2.2 nmoles or more, for example, 2.4 nmoles or more, for example, 2.6 nmoles or more, for example, 2.8 nmoles, for example, 3.0 nmoles or more, for example,~~ A method as claimed in claim 53, which comprises administering PYY or an agonist thereof to the subject subcutaneously at a dose of 0.1 nmoles up to 3.2 nmoles per kg body weight.

57. (Currently Amended) ~~Use as claimed in claim 53 or claim 56, wherein the PYY or agonist thereof is administered peripherally in an amount of up to 3.0 nmoles per kg body weight, for example, up to 2.8 nmoles, for example, up to 2.6 nmoles, for example, up to 2.4 nmoles, for example, up to 2.2 nmoles, for example, up to 2.0 nmoles, for example, up to 1.8 nmoles, for example, up to 1.4 nmoles, for example, up to 1.2 nmoles, for example, up to 1.0 nmoles, for example, up to 0.8 nmoles, for example, up to 0.6 nmoles, for example, up to 0.4 nmoles, for~~

~~example, up to 0.2~~ A method as claimed in claim 53, which comprises administering PYY or an agonist thereof to the subject subcutaneously at a dose of 0.2 nmoles up to 3.0 nmoles per kg body weight.

58. (New) A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 1.8 nmoles per kg body weight of the subject.

59. (New) A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 2.0 nmoles per kg body weight of the subject.

60. (New) A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 2.2 nmoles per kg body weight of the subject.

61. (New) A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 2.4 nmoles per kg body weight of the subject.

62. (New) A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 2.6 nmoles per kg body weight of the subject.



63. (New) A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 2.8 nmoles per kg body weight of the subject.

64. (New) A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 3.0 nmoles per kg body weight of the subject.

65. (New) A method as claimed in claim 21, wherein the PYY or agonist thereof and/or the GLP-1 or agonist thereof is administered peripherally at a dose of 3.2 nmoles per kg body weight of the subject.

66. (New) A method as claimed in claim 4, wherein a therapeutically effective amount of PYY<sub>3-36</sub> is administered to said subject.

67. (New) A method as claimed in claim 14, wherein peripheral administration comprises subcutaneous administration.

68. (New) The method of claim 1, wherein peripheral administration comprises peripheral injection in a pulse dose.

69. (New) The method of claim 1, wherein peripheral administration comprises administration in a slow, sustained or controlled release preparation or from a pump or implantable drug infusion device.

70. (New) A method as claimed in claim 1, wherein peripherally administering PYY or the agonist thereof comprises administering about 0.5 to about 135 pmol of PYY or the agonist thereof per kilogram body weight of the subject.

71. (New) A method as claimed in claim 18, wherein PYY or the agonist thereof is peripherally administered to the subject in a multitude of doses, wherein each dose in the multitude of doses comprises administration of about 0.5 to about 135 pmol of said PYY or agonist thereof per kilogram of body weight at least about 30 minutes prior to a meal.

72. (New) A method as claimed in claim 20, wherein the PYY or the agonist thereof and the GLP-1 or agonist thereof is administered in an amount sufficient to decrease calorie intake in said subject for a period of about 2 to 12 hours.

73. (New) A method as claimed in claim 1, further comprising administering a therapeutically effective amount of an additional appetite suppressant to said subject.

74. (New) A method as claimed in claim 1, further comprising administering a food intake-reducing agent, plasma glucose-lowering agent or plasma lipid-altering agent to said subject.

75. (New) A method for decreasing appetite, reducing hunger or sensations of hunger, increasing satiety or sensations of satiety, decreasing food intake, decreasing calorie intake, reducing nutrient availability, increasing energy expenditure, preventing, reducing or treating weight gain, inducing or promoting weight loss, maintaining a desired body weight or a desired Body Mass Index, or reducing or preventing obesity in a subject, which comprises peripherally administering a therapeutically effective amount of PYY and a therapeutically effective amount of GLP-1 to the subject.

76. (New) A method for decreasing appetite, food intake or calorie intake in a subject, comprising peripherally administering to said subject an amount of PYY and an amount of GLP-1 effective to decrease appetite, food intake or calorie intake in said subject.